Data as of .
GNOM vs PBE: which is really different?
GNOM and PBE hold 30% of their weight in the same names, and GNOM returned more over the year.
ETFIQ Off-Index Score: PBE scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
30% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, GNOM and PBE hold 30% of their money in the same securities at the same weight.
| Holding | GNOM | PBE |
|---|---|---|
| ILLUMINA INC | 5.30% | 5.53% |
| NATERA INC | 5.13% | 5.70% |
| VERTEX PHARMACEUTICALS INC | 3.35% | 4.77% |
| QIAGEN N.V. | 3.13% | 2.81% |
| MODERNA INC | 7.99% | 2.75% |
| BIOMARIN PHARMACEUTICAL INC | 3.41% | 2.74% |
| VERACYTE INC | 2.33% | 2.56% |
| LEGEND BIOTECH CORP-ADR | 1.96% | 2.34% |
| GILEAD SCIENCES INC | 1.63% | 5.27% |
| SAREPTA THERAPEUTICS INC | 1.51% | 3.01% |
| Only in GNOM | Only in PBE |
|---|---|
| TWIST BIOSCIENCE CORP 7.40% | Biogen Inc 5.07% |
| 10X GENOMICS INC-CLASS A 6.53% | Regeneron Pharmaceuticals Inc 4.89% |
| GUARDANT HEALTH INC 5.78% | Royalty Pharma PLC 4.88% |
| GENSCRIPT BIOTECH CORP 4.29% | Amgen Inc 4.53% |
| BIO-TECHNE CORP 3.56% | Novavax Inc 3.03% |
| CRISPR THERAPEUTICS AG 2.89% | Exelixis Inc 2.91% |
| CARIS LIFE SCIENCES INC 2.72% | Halozyme Therapeutics Inc 2.91% |
| ARROWHEAD PHARMACEUTICALS IN 2.59% | TG Therapeutics Inc 2.91% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026 and Sep 19, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| GNOM | PBE | GNOM | PBE | GNOM | PBE | |
| 3 months | +27.6% | +13.2% | +25.4 pts | +11.0 pts | +30.1 pts | +15.7 pts |
| 6 months | +56.4% | +25.9% | +38.4 pts | +7.8 pts | +32.2 pts | +1.6 pts |
| 1 year | +77.5% | +36.2% | +60.9 pts | +19.6 pts | +55.7 pts | +14.4 pts |
| 3 years | +59.3% | +65.0% | −19.1 pts | −13.4 pts | −38.9 pts | −33.1 pts |
| Since launch | +9.8% | +492.4% | −185.2 pts | −311.1 pts | −297.4 pts | −1197.8 pts |
| GNOM Global X Genomics & Biotechnology ETF Holds 52 stocks in genomics and gene editing, 21% of its weight in S&P 500 companies | PBE Invesco Biotechnology & Genome ETF Holds 33 stocks in biotech, 30% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | Global X | Invesco |
| Theme | Genomics and gene editing | Biotech |
| In the S&P 500 | 20.9% | 30.0% |
| Active share vs the S&P 500 | 97.6% | 99.0% |
| In the Nasdaq-100 | 5.0% | 19.5% |
| Holdings | 52 | 33 |
| Top ten, share of the fund | 52.7% | 46.7% |
| Expense ratio | 0.50% | 0.59% |
| Fee for the differing part | 0.51% | 0.60% |
| Total return, 1 year | +77.5% | +36.2% |
| vs the S&P 500 | +60.9 pts | +19.6 pts |
| vs the Nasdaq-100 | +55.7 pts | +14.4 pts |
| Below its high | −39.6% | −3.9% |
| Net assets | $100m | $414m |
GNOM in plain words
By weight, 21% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 53% of the fund across 52 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +77.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 60.9 pts. It sits 39.6% below its all-time high of Feb 8, 2021.
PBE in plain words
By weight, 30% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 47% of the fund across 33 positions, as published by its issuer for Sep 19, 2026. Over the year to Sep 18, 2026 the fund returned +36.2% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 19.6 pts.
Questions people ask
- Do GNOM and PBE hold the same stocks?
- By their latest filings, 30% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, GNOM or PBE?
- GNOM has 21% of its weight in S&P 500 names and PBE has 30%, so PBE differs more from the index.
- Which is cheaper, GNOM or PBE?
- GNOM charges 0.50% a year and PBE charges 0.59%, so GNOM is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, GNOM against PBE, data as of Sep 18, 2026. https://etfiq.com/compare/themes/gnom-vs-pbe Free to use with attribution; the underlying files are at Open data.